HC Wainwright Has Negative Outlook of REGENXBIO Q3 Earnings

Posted by Geri Gentry on Aug 12th, 2026

REGENXBIO Inc. (NASDAQ:RGNX – Free Report) – HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for REGENXBIO in a research note issued on Monday, August 10th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($1.20) per share for the quarter, down from their previous estimate of $0.32. HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($3.95) per share. HC Wainwright also issued estimates for REGENXBIO’s Q4 2026 earnings at ($1.09) EPS, FY2026 earnings at ($3.65) EPS, Q1 2027 earnings at ($1.09) EPS, Q4 2027 earnings at ($0.94) EPS and FY2027 earnings at ($4.02) EPS.

REGENXBIO (NASDAQ:RGNX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.35. The business had revenue of $108.02 million for the quarter, compared to analysts’ expectations of $97.63 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%.

Other analysts have also issued reports about the stock. Zacks Research lowered shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Wall Street Zen upgraded shares of REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Saturday. Leerink Partners boosted their target price on REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Monday, June 22nd. Robert W. Baird boosted their target price on REGENXBIO from $27.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, June 22nd. Finally, Morgan Stanley restated an “overweight” rating and issued a $18.00 target price on shares of REGENXBIO in a research report on Friday. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, REGENXBIO has an average rating of “Moderate Buy” and a consensus price target of $23.73.

Check Out Our Latest Analysis on RGNX

REGENXBIO Stock Up 2.2%

Shares of RGNX opened at $10.65 on Wednesday. The firm has a market capitalization of $550.61 million, a PE ratio of -2.81 and a beta of 0.94. The firm has a 50-day moving average price of $10.17 and a 200 day moving average price of $9.34. REGENXBIO has a 52-week low of $5.45 and a 52-week high of $16.19.

Insider Activity at REGENXBIO

In related news, insider Steve Pakola sold 2,161 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $13.64, for a total transaction of $29,476.04. Following the completion of the sale, the insider directly owned 213,009 shares of the company’s stock, valued at $2,905,442.76. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 58,494 shares of company stock valued at $718,232. 14.22% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of REGENXBIO during the second quarter valued at $76,641,000. AQR Capital Management LLC increased its stake in REGENXBIO by 2,247.7% in the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after purchasing an additional 594,161 shares in the last quarter. State Street Corp increased its stake in REGENXBIO by 15.2% in the 4th quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company’s stock worth $32,929,000 after purchasing an additional 301,858 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in REGENXBIO during the 1st quarter worth about $2,305,000. Finally, GSK plc acquired a new stake in REGENXBIO during the 4th quarter worth about $3,909,000. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

(Get Free Report)

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

HC Wainwright Has Negative Outlook of REGENXBIO Q3 Earnings

REGENXBIO Stock Up 2.2%

Insider Activity at REGENXBIO

Institutional Inflows and Outflows

About REGENXBIO

See Also

You might be interested in: